ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.

ABECMA® Information and Resources

As a healthcare provider, you play a critical role in the ABECMA treatment process, helping RRMM patients navigate their journey with ABECMA. Get information and tools you need to help support your patients below.

From the treatment process to adverse event monitoring and management information, it’s here—so you can continue to guide your patients throughout their treatment journey.

RRMM=relapsed/refractory multiple myeloma.

Find Support and Resources for You and Your Patients with RRMM

Resources for you

Document Icon

HCP Brochure

Document Icon

Clinician Guide

Document Icon

AE Management Tool


Resources for your patients

Document Icon

Patient Brochure

Document Icon

Questions to Ask Your Doctor

Document Icon

Patient Eligibility Guide


Video Library


MOA Video Thumbnail

Patient-directed Video Library

Learn How ABECMA Is Made

How ABECMA® is Made Video Thumbnail

Meet Your ABECMA Care Team

Meet your ABECMA®  CAR T Care Team Video Thumbnail

ABECMA Patient Stories — Dana

Patient Stories with ABECMA®  CAR T - Dana Video Thumbnail

ABECMA Patient Stories — Mary

Patient Stories with ABECMA®  CAR T - Mary Video Thumbnail

Access and financial resources

Cell Therapy 360®

Dedicated to providing solutions-oriented support and knowledge to help patients throughout the CAR T cell therapy journey.

Bristol Myers Squibb’s Cell Therapy 360 program supports patients and caregivers throughout their treatment journey, from enrollment through the initial post-infusion monitoring period, with referral resources, patient support navigators, logistical support*, and financial support*.

*Eligibility requirements may apply.

Cell Therapy 360 enrollment

Patients may enroll in support programs offered through Cell Therapy 360 after a certified CAR T treatment center determines that ABECMA is the right treatment for them.

The support programs offered through Cell Therapy 360 are available only to people who are receiving a CAR T cell therapy from Bristol Myers Squibb, such as ABECMA. Certain restrictions and eligibility requirements apply.

CAR=chimeric antigen receptor.

Cell Therapy 360 Logo

Call us at 1-888-805-4555

Visit us at

CAR=chimeric antigen receptor.

Learn more about

See more ABECMA